AFT Pharmaceuticals Limited (NZE: AFT)

Market Cap	335.57M
Revenue (ttm)	195.41M
Net Income (ttm)	15.61M
Shares Out	104.87M
EPS (ttm)	0.15
PE Ratio	21.50
Forward PE	19.77
Dividend	0.02 (0.50%)
Ex-Dividend Date	Jun 19, 2024

Volume	4,407
Open	3.160
Previous Close	3.180
Day's Range	3.160 - 3.180
52-Week Range	2.600 - 3.850
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 21, 2024

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, vitamins, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 110
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: AFT

Financial Performance

In 2023, AFT Pharmaceuticals's revenue was 195.41 million, an increase of 24.75% compared to the previous year's 156.64 million. Earnings were 15.61 million, an increase of 46.51%.